Ocular myasthenia: Diagnosis, treatment, and pathogenesis

Neurologist

Volumn 12, Issue 5, 2006, Pages 231-239

  Kusner, Linda L ^b   Puwanant, Araya ^b   Kaminski, Henry J ^a,b,c  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Extraocular muscle; Myasthenia gravis; Ocular myasthenia

Indexed keywords

ATROPINE; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EDROPHONIUM; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PREDNISONE; PYRIDOSTIGMINE; TACROLIMUS;

ABDOMINAL CRAMP; ANTIBODY BLOOD LEVEL; BRADYCARDIA; BRAIN STEM INJURY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIPLOPIA; DRUG CONTRAINDICATION; ELECTRODIAGNOSIS; EXTRAOCULAR MUSCLE; HUMAN; LACRIMATION DISORDER; MUSCLE WEAKNESS; MYASTHENIA; MYASTHENIA GRAVIS; NAUSEA; OCULAR MYASTHENIA; OPHTHALMOPLEGIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PTOSIS; REVIEW; SALIVATION DISORDER; SIDE EFFECT; SWEATING; SYNCOPE; VOMITING;

HUMANS; MYASTHENIA GRAVIS; OCULOMOTOR MUSCLES;

EID: 33748976752     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000240856.03505.b5     Document Type: Review

References (94)

1. MacDonald BK, Cockerell OC, Sander JW, et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123:665-676.
2. Somnier F, Keiding N, Paulson O. Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive study. Arch Neurol. 1991;48:733-739.
3. Phillips L, Torner J, Anderson M, et al. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42:1888-1893.
4. Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996;47:1233-1238.
5. Christensen P, Jensen T, Tsiropoulos I, et al. Incidence and prevalence of myasthenia gravis in western Denmark 1975 to 1989. Neurology. 1993;43:1779-1783.
6. Mantegazza R, Baggi F, Antozzi C, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci. 2003;998:413-423.
7. Grob D. Natural history of myasthenia gravis. In: Engel AG, ed. Myasthenia Gravis and Myasthenic Disorders. New York: Oxford University Press; 1999:131-154.
8. Matsuda M, Dohi-Iijima N, Nakamura A, et al. Increase in incidence of elderly-onset patients with myasthenia gravis in Nagano Prefecture, Japan. Intern Med. 2005;44:572-577.
9. Vincent A, Clover L, Buckley C, et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry. 2003;74:1105-1108.
10. Chiu H-C, Vincent A, Nemsom-Davis J, et al. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology. 1987;37:1854-1857.
11. Hawkins BR, Yu YL, Wong V, et al. Possible evidence of a variant of myasthenia gravis based on HLA and acetylcholine receptor antibody in Chinese patients. Q J Med. 1989;70:235-241.
12. Wong V, Hawkins BR, Yu YL. Myasthenia gravis in Hong Kong Chinese. Acta Neurol Scand. 1992;86:68-72.
13. Barton JJ, Fouladvand M. Ocular aspects of myasthenia gravis. Semin Neurol. 2000;20:7-20.
14. Bever CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol. 1983;14:516-519.
15. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997;244:112-118.
16. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003;60:243-248.
17. Oosterhuis H. The natural course of myasthenia gravis. J Neurol Neurosurg Psychiatry. 1989;52:1121-1127.
18. Evoli A, Tonali P, Bartoccioni E, et al. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand. 1988;77:31-35.
19. Elrod RD, Weinberg DA. Ocular myasthenia gravis. Ophthalmol Clin North Am. 2004;17:275-309, v.
20. Fouladvand M, Ledoux D, Barton JS. Ocular myasthenia gravis. Comprehensive Opthalmology Update. 2005;6:25-36.
21. Daroff R. Ocular myasthenia. In: Kaminski HJ, ed. Myasthenia Gravis and Related Disorders. Totowa, NJ: Humana Press; 2003:115-128.
22. Leigh RJ, Zee DS. The Neurology of Eye Movements: Contemporary Neurology Series. Philadelphia: F.A. Davis; 1999:561.
23. Barton JJ, Jama A, Sharpe JA. Saccadic duration and intrasaccadic fatigue in myasthenic and nonmyasthenic ocular palsies. Neurology. 1995;45:2065-2072.
24. Hirano M, DiMauro S. ANT1, twinkle, POLG, and TP: new genes open our eyes to ophthalmoplegia. Neurology. 2001;57:2163-2165.
25. Daroff RB. The office Tensilon test for ocular myasthenia gravis. Arch Neurol. 1986;43:843-844.
26. Pascuzzi RM. The edrophonium test. Semin Neurol. 2003;23:83-88.
27. Ing EB, Ing SY, Ing T, et al. The complication rate of edrophonium testing for suspected myasthenia gravis. Can J Ophthalmol. 2000;35:141-144.
28. Golnik KC, Pena R, Lee AG, et al. An ice test for the diagnosis of myasthenia gravis. Ophthalmology. 1999;106:1282-1286.
29. Ellis FD, Hoyt CS, Ellis FJ, et al. Extraocular muscle responses to orbital cooling (ice test) for ocular myasthenia gravis diagnosis. J AAPOS. 2000;4:271-281.
30. Odell JG, Winterkorn JMS, Behrens MM. The sleep test for myasthenia gravis: safe alternative to Tensilon. J Clin Neurol Opthalmol. 1991;11:288-292.
31. Kubis KC, Danesh-Meyer HV, Savino PJ, et al. The ice test versus the rest test in myasthenia gravis. Ophthalmology. 2000;107:1995-1998.
32. Howard FJ, Lennon V, Finley J, et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci. 1987;505:526-538.
33. Lennon V. Serologic profile of myasthenia gravis and distinction from Lambert-Eaton myasthenic syndrome. Neurology. 1997;48(suppl 5):S23-27.
34. Vincent A, Bowen J, Newsom-Davis J, et al. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol. 2003;2:99-106.
35. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304-2311.
36. Zhou L, McConville J, Chaudhry V, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve. 2004;30:55-60.
37. Liyanage Y, Hoch W, Beeson D, et al. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve. 2002;25:4-16.
38. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365-368.
39. Caress JB, Hunt CH, Batish SD. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol. 2005;62:1002-1003.
40. Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol. 2004;24:31-39.
41. Katirji B, Kaminski HJ. An electrodiagnostic approach to the patient with neuromuscular junction disorder. Neurol Clin. 2002;20:557-586.
42. Ukachoke C, Ashby P, Basinski A, et al. Usefulness of single fiber EMG for distinguishing neuromuscular from other causes of ocular muscle weakness. Can J Neurol Sci. 1994;21:125-128.
43. Sanders DB. Electrophysiologic tests of neuromuscular transmission. Suppl Clin Neurophysiol. 2004;57:167-169.
44. Sanders DB, Stalberg EV. AAEM minimonograph #25: single-fiber electromyography. Muscle Nerve. 1996;19:1069-1083.
45. Weinberg DH, Rizzo JF 3rd, Hayes MT, et al. Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve. 1999;22:1222-1227.
46. Ohtsuki H, Hasebe S, Okano M, et al. Strabismus surgery in ocular myasthenia gravis. Ophthalmologica. 1996;210:95-100.
47. Bentley CR, Dawson E, Lee JP. Active management in patients with ocular manifestations of myasthenia gravis. Eye. 2001;15:18-22.
48. Sommer N, Melms A, Weller M, et al. Ocular myasthenia gravis: a critical review of clinical and pathophysiological aspects. Doc Ophthalmol. 1993;84:309-333.
49. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62:156-162.
50. Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005;89:1330-1334.
51. Kupersmith MJ. Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease? J Neurol Sci. 2004;217:123-124.
52. Mee J, Paine M, Byrne E, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23:251-255.
53. Papapetropoulos TH, Ellul J, Tsibri E. Development of generalized myasthenia gravis in patients with ocular myasthenia gravis. Arch Neurol. 2003;60:1491-1492.
54. Tackenberg B, Hemmer B, Oertel WH, et al. Immunosuppressive treatment of ocular myasthenia gravis. BioDrugs. 2001;15:369-378.
55. Kaminski HJ, Daroff RB. Controversies in neurology: treatment of ocular myasthenia: steroids only when compelled. Arch Neurol. 2000;57:752-753.
56. Agius MA. Treatment of ocular myasthenia with corticosteroids: yes. Arch Neurol. 2000;57:750-751.
57. Monsul NT, Patwa HS, Knorr AM, et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217:131-133.
58. Wakata N, Iguchi H, Sugimoto H, et al. Relapse of ocular symptoms after remission of myasthenia gravis: a comparison of relapsed and complete remission cases. Clin Neurol Neurosurg. 2003;105:75-77.
59. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis: Myasthenia Gravis Study Group. Neurology. 1998;50:1778-1783.
60. Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol. 1988;235:449-453.
61. Hohlfeld R, Michels M, Heininger K, et al. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology. 1988;38:258-261.
62. Mertens HG, Hertel G, Reuther P, et al. Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci. 1981;377:691-699.
63. Matell G. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann N Y Acad Sci. 1987;505:589-594.
64. Ciafaloni E, Nikhar NK, Massey JM, et al. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology. 2000;55:448-450.
65. Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316:719-724.
66. Ciafaloni E, Massey JM, Tucker-Lipscomb B, et al. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology. 2001;56:97-99.
67. Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001;56:94-96.
68. Meriggioli MN, Rowin J, Richman JG, et al. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003;998:494-499.
69. Konishi T, Yoshiyama Y, Takamori M, et al. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry. 2005;76:448-450.
70. Schumm F, Wiethölter H, Fateh-Moghadam A, et al. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry. 1985;48:332-337.
71. Roberts PF, Venuta F, Rendina E, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001;122:562-568.
72. Hughes BW, Moro De Casillas ML, Kaminski HJ. Pathophysiology of myasthenia gravis. Semin Neurol. 2004;24:21-30.
73. Limburg PC, The TC, Hummel-Teppel E, et al. Anti-acetylcholine receptor antibodies in myasthenia gravis, I: relation to clinical parameters in 250 patients. J Neurol Sci. 1983;58:357-370.
74. Gunji K, Skolnick C, Bednarczuk T, et al. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine receptor antibody-negative patients. Clin Immunol Immunopathol. 1998;87:276-281.
75. Kaminski HJ, Kusner LL, Block CH. Expression of acetylcholine receptor isoforms at extraocular muscle endplates. Invest Ophthalmol Vis Sci. 1996;37:345-351.
76. Kaminski HJ, Li Z, Richmonds C, et al. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol. 2004;189:333-342.
77. Porter JD, Khanna S, Kaminski HJ, et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci U S A. 2001;98:12062-12067.
78. Wang Z, Diethelm-Okita B, Okita D, et al. T-cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis. J Neuroimmunol. 2000;108:29-39.
79. Cheng G, Porter JD. Transcriptional profile of rat extraocular muscle by serial analysis of gene expression. Invest Ophthalmol Vis Sci. 2002;43:1048-1058.
80. Fischer MD, Gorospe JR, Felder E, et al. Expression profiling reveals metabolic and structural components of extraocular muscles. Physiol Genomics. 2002;9:71-84.
81. Fischer MD, Budak MT, Bakay M, et al. Definition of the unique human extraocular muscle allotype by expression profiling. Physiol Genomics. 2005;22:283-291.
82. Khanna S, Cheng G, Gong B, et al. Genome-wide transcriptional profiles are consistent with functional specialization of the extraocular muscle layers. Invest Ophthalmol Vis Sci. 2004;45:3055-3066.
83. Khanna S, Porter JD. Conservation of synapse-signaling pathways at the extraocular muscle neuromuscular junction. Ann N Y Acad Sci. 2002;956:394-396.
84. Spencer RF, Porter JD. Structural organization of the extraocular muscles. In: Buttner-Ennever J, ed. Neuroanatomy of the Oculomotor System. Amsterdam: Elsevier; 1988:33-79.
85. Spencer RF, Porter JD. Biological organization of the extraocular muscles. Prog Brain Res. 2005;151:43-80.
86. Kaminski HJ, Li Z, Richmonds C, et al. Susceptibility of ocular tissues to autoimmune diseases. Ann N Y Acad Sci. 2003;998:362-374.
87. Losen M, Stassen MH, Martinez-Martinez P, et al. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain. 2005;128:2327-2337.
88. Scuderi F, Marino M, Colonna L, et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest. 2002;82:1139-1146.
89. Wooten GF, Reis DJ. Blood flow in extraocular muscle of cat. Arch Neurol. 1972;26:350-352.
90. Wilcox LM, Keough EM, Connolly RJ, et al. Comparative extraocular muscle blood flow. J Exp Zool. 1981;215:87-90.
91. Nicholson-Weller A, Wang CE. Structure and function of decay accelerating factor CD55. J Lab Clin Med. 1994;123:485-491.
92. Lin F, Kaminski H, Conti-Fine B, et al. Enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest. 2002;110:1269-1274.
93. Conti-Fine BM, Kaminski HJ. Autoimmune neuromuscular transmission disorders: myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum. 2001;7:56-93.
94. Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol. 2001;64:393-429.